NEW YORK CITY, NY / ACCESS Newswire / March 5, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...
Shares of Regeneron Pharmaceuticals Inc. REGN rose 1.73% to $687.15 Wednesday, on what proved to be an all-around favorable ...
We recently published a list of 10 Worst Performing Large Cap Stocks to Buy According to Analysts. In this article, we are ...
At the heart of the controversy is Regeneron's alleged practice of paying credit card fees to distributors, on the condition that these fees were not passed on to Eylea customers. This arrangement, ...
Zacks Investment Research on MSN2d
Regeneron Gets Positive CHMP Opinion for Multiple Myeloma DrugRegeneron Pharmaceuticals, Inc. REGN obtained positive opinion for its pipeline candidate linvoseltamab from the European ...
The Federal Circuit upheld a preliminary injunction blocking the launch of a Celltrion Inc. biosimilar version to Regeneron ...
Regeneron’s gene therapy, dubbed DB-OTO, is a cell-selective AAV gene therapy for children with hearing loss stemming from a ...
Ten of 11 children born with a rare form of congenital hearing loss experienced improvements after receiving the company’s ...
A gene therapy from Regeneron Pharmaceuticals Inc. improved hearing in nearly all deaf children in a clinical trial, results ...
This was the stock's fifth consecutive day of losses.
The Mineola Board of Education recognized Fatimah Badoolah, a senior at Mineola High School, who is a 2025 Regeneron Science ...
OTO, is one of several early-stage gene therapies being developed to treat relatively straight-forward causes of genetic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback